TB-500: preclinical and in-vitro studies
8 published studies on TB-500, limited by rule to animal models and cell-based (in vitro) work indexed in PubMed, spanning 2021 to 2026 across 8 journals. Human trials, case reports and literature overviews are excluded. Titles appear as published; each links to its PubMed record and, where one is registered, its DOI.
- 8studies listed
- 8with an animal model
- 7with in-vitro work
- 2021 to 2026publication years
- 8journals
Evidence table
Studies by model
- In vitro · 7 studies
- Mice · 6 studies
- Rats · 1 study
- Chickens · 1 study
What this index does not include
Human research of any kind: publications typed by PubMed as human studies or case reports, and papers whose titles or abstracts describe human subjects, are removed by rule. Literature overviews, meta-analyses, editorials and letters are removed because they summarise rather than report. Papers whose titles contain usage or outcome language that would not pass this site's research-use-only copy rules are dropped rather than reworded, since a published title is a fact that cannot be edited.
Nothing on this page is a statement about effects in humans, a recommendation, or a description of the material supplied. TB-500 is supplied for laboratory research only.
How this index is built
PubMed is searched on the names the literature uses for TB-500 (thymosin beta-4, thymosin beta 4, thymosin β4, Tβ4, TB-500), restricted to records indexed to an animal or cell model, in English, with an abstract. Clinical publication types, human-subject language and overview-type publications are excluded. The compound must be named in the title. Candidates are ranked by title match, indexing quality and year; the shortlist is read by a person before it is published, and a small blocklist holds records rejected on that read. The list was resolved on 2026-10-12 and is re-run deliberately, never on a timer.
Questions
Are there human studies of TB-500 in this index?
No, by design. This index lists animal and cell-based research only. Publications typed as human studies, case reports or literature overviews, and papers whose titles or abstracts describe human subjects, are excluded by rule before anything is listed. Eon Peptides supplies TB-500 for laboratory research and makes no statement about use in humans.
Which research models appear most often for TB-500?
Across the 8 studies listed: In vitro (7), Mice (6), Rats (1), Chickens (1). A model label is taken from PubMed's indexing of each paper, or from its title and abstract when the record is too new to be indexed. It describes the study, not the material.
How are the studies selected?
A PubMed search on the published names of the compound (thymosin beta-4, thymosin beta 4, thymosin β4, Tβ4, TB-500) is filtered to records indexed to an animal or cell model, with clinical publication types, human-subject language and overview-type publications removed. The compound must be named in the title. Remaining records are ranked by title match, indexing quality and year, and the top 8 are listed after a manual read. The list was resolved against PubMed on 2026-10-12.
Does a listing here say anything about the TB-500 Eon Peptides sells?
No. A listing records that a study was published and what it examined. It says nothing about the properties, quality or intended use of any material. What Eon Peptides does document about its own TB-500 is on the certificate pages: lot-level identity and purity results from independent laboratories.
Related pages
- TB-500 in the catalogueSizes, price and the current certificate
- TB-500 research monographMolecular data, mechanisms studied, specification
- TB-500 certificate recordEvery documented third-party HPLC result for this compound
For research use only. Not for human or veterinary use. Preclinical and in-vitro studies only: animal models and cell-based work indexed in PubMed. Human trials, case reports and literature overviews are excluded by rule.